Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
| ▸ | CYBB | P04839 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419762 | 0.92 | CYP1A2 (0.45) | HTR1BTP53MAPK1RAB9AMELK | |
| SCHEMBL15036883 | 0.79 | TAAR1 (0.48) | TAAR1 | |
| SCHEMBL16419784 | 0.78 | HTR1B (0.40) | HTR1BMAPK1KDM4EMELKSMN1; SMN2 | |
| SCHEMBL4355741 | 0.74 | HTR1B (0.40) | HTR1BTP53KDM4ESMN1; SMN2MAOA | |
| SCHEMBL11017858 | 0.73 | TP53 (0.79) | HTR1BTP53MAPK1RAB9AKDM4E | |
| SCHEMBL11763590 | 0.72 | KDM4E (0.73) | HTR1BTP53MAPK1RAB9AKDM4E | |
| SCHEMBL16419742 | 0.72 | LTA4H (0.49) | MAPK1RAB9APTPN1TAAR1SMN1; SMN2 | |
| SCHEMBL16419754 | 0.72 | BCHE (0.40) | HTR1BMAPK1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL10679411 | 0.72 | LSS (0.59) | TAAR1 | |
| SCHEMBL10682119 | 0.71 | LTA4H (0.55) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469616-B2 | Cyclic compounds and methods of making and using the same | CELLCEUTIX CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2013090185-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | POLYMEDIX, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MUC1, TLR3, ALG1 | HTR1B 4113/4885TP53 725/4885MAPK1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.